graph Evidence gap map comparisons
trastuzumab based treatment
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
Comparator:  vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel; 
Risk of bias:  low;   some concerns;   high;  NA;